Doctor reviewing results with one of her patients on a tablet

Decades of research supported by ongoing clinical studies

Clinical outcomes

Peer-reviewed research evaluating the effect of Virta demonstrates that patients can safely improve health outcomes associated with type 2 diabetes, obesity, atherogenic dyslipidemia, hypertension, and inflammation. By impacting these chronic conditions, Virta improves several risk factors for type 2 diabetes and cardiovascular disease.

Type 2 Diabetes

While reducing and eliminating glycemic control medications, Virta patients lowered HbA1c by 1.3% on average after one year and improved insulin resistance measured by HOMA-IR. 60% of patients enrolled one year attained an HbA1c below 6.5% without the use of diabetes medications other than metformin.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar charts showing comparison of Virta to Usual Care: Change in metabolic markers and medication use

Obesity

Excess weight represents risk for both type 2 diabetes and cardiovascular disease. Virta patients with type 2 diabetes sustained the loss of 12% of their body weight over the year. The prevalence of class III obesity among participants was reduced from 46% to 20%.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar chart showing comparison of Virta to Usual Care: Weight loss

Atherogenic Dyslipidemia

Characterized by high triglycerides and low HDL-C, atherogenic dyslipidemia is common among patients with insulin resistance and represents increased cardiovascular risk. Virta patients improved both markers, with the TG/HDL-C ratio declining from 4.7 to 3 on average.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar charts showing comparison of Virta to Usual Care: Atherogenic Dyslipidemia

Hypertension

Elevated blood pressure, especially in the presence of additional risk factors, increases cardiovascular risk. Virta patients reduced blood pressure and the need for antihypertensive medication, especially diuretics.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar charts showing comparison of Virta to Usual Care: Hypertension

Inflammation

Inflammation is a common underlying factor in obesity, insulin resistance, hypertension, and cardiovascular disease. C-reactive protein and white blood cell count, common markers of inflammation, were significantly reduced in Virta patients with type 2 diabetes.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar charts showing comparison of Virta to Usual Care: Inflammation

Safety

A common concern in the treatment of type 2 diabetes is hypoglycemia. In our clinical trial, no hypoglycemic events requiring assistance were reported. Additionally, treatment at Virta resulted in neutral or positive effects on markers of kidney and liver function.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar charts showing comparison of Virta to Usual Care: Safety measures

Cardiovascular Risk Measures

10-year ASCVD risk score improves after one year of the Virta Treatment. Most lipid and lipoprotein risk markers improved or were unaffected; an undesirable change was observed in one marker.¹

Chart legend showing Virta (blue) and Usual care (gray)
Bar charts showing comparison of Virta to Usual Care: Cardiovascular risk markers

Publications

Advancing science and medicine

Virta Health Research is committed to improving patient health outcomes by advancing the understanding of chronic metabolic conditions and how to best treat them, while providing evidence to inform clinicians and patients in their care decisions.
Visit the Virta Health blog to learn more about our thoughts on the latest research and hot topics in the field.
Doctor sharing information with her patient
Citations and Footnotes
  1. Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.